| Literature DB >> 19955659 |
Il-Kang Na1, Sydney X Lu, Nury L Yim, Gabrielle L Goldberg, Jennifer Tsai, Uttam Rao, Odette M Smith, Christopher G King, David Suh, Daniel Hirschhorn-Cymerman, Lia Palomba, Olaf Penack, Amanda M Holland, Robert R Jenq, Arnab Ghosh, Hien Tran, Taha Merghoub, Chen Liu, Gregory D Sempowski, Melissa Ventevogel, Nicole Beauchemin, Marcel R M van den Brink.
Abstract
Thymic graft-versus-host disease (tGVHD) can contribute to profound T cell deficiency and repertoire restriction after allogeneic BM transplantation (allo-BMT). However, the cellular mechanisms of tGVHD and interactions between donor alloreactive T cells and thymic tissues remain poorly defined. Using clinically relevant murine allo-BMT models, we show here that even minimal numbers of donor alloreactive T cells, which caused mild nonlethal systemic graft-versus-host disease, were sufficient to damage the thymus, delay T lineage reconstitution, and compromise donor peripheral T cell function. Furthermore, to mediate tGVHD, donor alloreactive T cells required trafficking molecules, including CCR9, L selectin, P selectin glycoprotein ligand-1, the integrin subunits alphaE and beta7, CCR2, and CXCR3, and costimulatory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecule 1. We found that radiation in BMT conditioning regimens upregulated expression of the death receptors Fas and death receptor 5 (DR5) on thymic stromal cells (especially epithelium), while decreasing expression of the antiapoptotic regulator cellular caspase-8-like inhibitory protein. Donor alloreactive T cells used the cognate proteins FasL and TNF-related apoptosis-inducing ligand (TRAIL) (but not TNF or perforin) to mediate tGVHD, thereby damaging thymic stromal cells, cytoarchitecture, and function. Strategies that interfere with Fas/FasL and TRAIL/DR5 interactions may therefore represent a means to attenuate tGVHD and improve T cell reconstitution in allo-BMT recipients.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19955659 PMCID: PMC2798682 DOI: 10.1172/JCI39395
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808